{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:53:20Z","timestamp":1792601600639,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.micpath.2023.106090","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T19:13:47Z","timestamp":1680290027000},"page":"106090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis"],"prefix":"10.1016","volume":"179","author":[{"given":"Theodoros","family":"Karampatakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Tsergouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Lowrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.micpath.2023.106090_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jgar.2015.01.006","article-title":"Carbapenem-resistant Klebsiella pneumoniae infections in a Greek intensive care unit: molecular characterisation and treatment challenges","volume":"3","author":"Katsiari","year":"2015","journal-title":"Journal of global antimicrobial resistance"},{"key":"10.1016\/j.micpath.2023.106090_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics9080514","article-title":"Clinical and economic burden of carbapenem-resistant infection or colonization caused by Klebsiella pneumoniae, Pseudomonas aeruginosa, acinetobacter baumannii: a multicenter study in China","volume":"9","author":"Zhen","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.micpath.2023.106090_bib3","series-title":"Clinical Microbiology and Infection","first-page":"268","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"vol. 18","author":"Magiorakos","year":"2012"},{"key":"10.1016\/j.micpath.2023.106090_bib4","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2217\/fmb-2016-0042","article-title":"Molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in Greece","volume":"11","author":"Karampatakis","year":"2016","journal-title":"Future Microbiol."},{"key":"10.1016\/j.micpath.2023.106090_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1586\/eri.12.162","article-title":"Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art","volume":"11","author":"Petrosillo","year":"2013","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"10.1016\/j.micpath.2023.106090_bib6","doi-asserted-by":"crossref","first-page":"8 e1","DOI":"10.1016\/j.ijantimicag.2008.11.006","article-title":"Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies","volume":"34","author":"Entenza","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.micpath.2023.106090_bib7","first-page":"10","article-title":"An update on eight \"new\" antibiotics against multidrug-resistant gram-negative bacteria","author":"Yusuf","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.micpath.2023.106090_bib8","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ijantimicag.2018.11.015","article-title":"Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam","volume":"53","author":"De la Calle","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.micpath.2023.106090_bib9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2146\/news150023","article-title":"Ceftazidime with beta-lactamase inhibitor approved for complicated infections","volume":"72","author":"Thompson","year":"2015","journal-title":"Am. J. Health Syst. Pharm. : AJHP : official journal of the American Society of Health-System Pharmacists"},{"key":"10.1016\/j.micpath.2023.106090_bib10","doi-asserted-by":"crossref","first-page":"ofz149","DOI":"10.1093\/ofid\/ofz149","article-title":"Randomized trial of ceftazidime-avibactam vs meropenem for treatment of hospital-acquired and ventilator-associated bacterial pneumonia (REPROVE): analyses per US FDA-specified end points","volume":"6","author":"Torres","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.micpath.2023.106090_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1556\/1886.2020.00022","article-title":"Review of therapeutic options for infections with carbapenem-resistant Klebsiella pneumoniae","volume":"10","author":"Bandick","year":"2020","journal-title":"European journal of microbiology & immunology"},{"key":"10.1016\/j.micpath.2023.106090_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40779-020-00238-8","article-title":"Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?","volume":"7","author":"Ma","year":"2020","journal-title":"Military Medical Research"},{"key":"10.1016\/j.micpath.2023.106090_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069930","article-title":"A re-analysis of the Cochrane Library data: the dangers of unobserved heterogeneity in meta-analyses","volume":"8","author":"Kontopantelis","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.micpath.2023.106090_bib16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.micpath.2023.106090_bib17","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"key":"10.1016\/j.micpath.2023.106090_bib19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jgar.2021.04.022","article-title":"Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: ceftazidime-avibactam against CR-KP infections","volume":"26","author":"Gu","year":"2021","journal-title":"Journal of global antimicrobial resistance"},{"key":"10.1016\/j.micpath.2023.106090_bib20","first-page":"61","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","author":"Shields","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2023.106090_bib21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin. Infect. Dis. : an official publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.micpath.2023.106090_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13054-020-2742-9","article-title":"Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae","volume":"24","author":"Falcone","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.micpath.2023.106090_bib23","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-beta-lactamase-producing enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin. Infect. Dis. : an official publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.micpath.2023.106090_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.780940","article-title":"Efficacy of ceftazidime-avibactam versus polymyxin B and risk factors affecting clinical outcomes in patients with carbapenem-resistant Klebsiella pneumoniae infections a retrospective study","volume":"12","author":"Fang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.micpath.2023.106090_bib25","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jac\/dkaa503","article-title":"Ceftazidime\/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study","volume":"76","author":"Karaiskos","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.micpath.2023.106090_bib26","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1007\/s40121-021-00542-3","article-title":"Ceftazidime-avibactam-based versus tigecycline-based regimen for the treatment of carbapenem-resistant Klebsiella pneumoniae-induced pneumonia in critically ill patients","volume":"10","author":"Shi","year":"2021","journal-title":"Infectious diseases and therapy"},{"key":"10.1016\/j.micpath.2023.106090_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02320-19","article-title":"Ceftazidime-avibactam to treat life-threatening infections by carbapenem-resistant pathogens in critically ill mechanically ventilated patients","volume":"64","author":"Tsolaki","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2023.106090_bib28","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.2147\/IDR.S343505","article-title":"Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant Klebsiella pneumoniae infection after kidney transplantation","volume":"14","author":"Zhang","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.micpath.2023.106090_bib29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin. Infect. Dis. : an official publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.micpath.2023.106090_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12874-018-0495-9","article-title":"Methods to systematically review and meta-analyse observational studies: a systematic scoping review of recommendations","volume":"18","author":"Mueller","year":"2018","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.micpath.2023.106090_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002028","article-title":"Epidemiology and reporting characteristics of systematic reviews of biomedical research: a cross-sectional study","volume":"13","author":"Page","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.micpath.2023.106090_bib32","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2023.106090_bib33","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3389\/fmicb.2014.00551","article-title":"A new strategy to fight antimicrobial resistance: the revival of old antibiotics","volume":"5","author":"Cassir","year":"2014","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2023.106090_bib34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijantimicag.2010.10.031","article-title":"Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay","volume":"37","author":"Pournaras","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.micpath.2023.106090_bib35","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/jac\/dky124","article-title":"Efficacy and safety of ceftazidime\/avibactam: a systematic review and meta-analysis","volume":"73","author":"Sternbach","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.micpath.2023.106090_bib36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1473-3099(17)30748-X","article-title":"Ceftazidime-avibactam versus meropenem for the treatment of nosocomial pneumonia","volume":"18","author":"Kalil","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2023.106090_bib37","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1128\/AAC.02429-13","article-title":"Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012","volume":"58","author":"Sader","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2023.106090_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/CE.S40698","article-title":"Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections","volume":"9","author":"Lagace-Wiens","year":"2014","journal-title":"Core Evid."},{"key":"10.1016\/j.micpath.2023.106090_bib39","series-title":"How to Interpret Results of Meta-Analysis","author":"Hak","year":"2016"},{"key":"10.1016\/j.micpath.2023.106090_bib40","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ijantimicag.2018.07.004","article-title":"Evaluation of the efficacy and safety of ceftazidime\/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis","volume":"52","author":"Zhong","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.micpath.2023.106090_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.10.023","article-title":"Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime\/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases","volume":"55","author":"Benchetrit","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.micpath.2023.106090_bib42","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jgar.2020.10.019","article-title":"Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: last resort therapy?","volume":"23","author":"Bocanegra-Ibarias","year":"2020","journal-title":"Journal of global antimicrobial resistance"},{"key":"10.1016\/j.micpath.2023.106090_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics10081012","article-title":"The revival of aztreonam in combination with avibactam against metallo-beta-lactamase-producing gram-negatives: a systematic review of in vitro studies and clinical cases","volume":"10","author":"Mauri","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.micpath.2023.106090_bib44","article-title":"Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant enterobacterales bloodstream infection: a systematic review and meta-analysis","volume":"10","author":"Chen","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.micpath.2023.106090_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01964-16","article-title":"Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms","volume":"61","author":"Temkin","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2023.106090_bib46","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jiph.2022.02.003","article-title":"Analysis of the clinical application of ceftazidime-avibactam in China","volume":"15","author":"Wang","year":"2022","journal-title":"Journal of infection and public health"},{"key":"10.1016\/j.micpath.2023.106090_bib47","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/00365548.2013.861608","article-title":"Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients","volume":"46","author":"Balandin Moreno","year":"2014","journal-title":"Scand. J. Infect. Dis."},{"key":"10.1016\/j.micpath.2023.106090_bib48","article-title":"Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens","volume":"97","author":"Chen","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.micpath.2023.106090_bib49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/ebmental-2019-300129","article-title":"Challenges in meta-analyses with observational studies","volume":"23","author":"Metelli","year":"2020","journal-title":"Evid. Base Ment. Health"},{"key":"10.1016\/j.micpath.2023.106090_bib50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2288-11-22","article-title":"Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study","volume":"11","author":"Schroll","year":"2011","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.micpath.2023.106090_bib51","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12941-017-0191-3","article-title":"Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae","volume":"16","author":"Xu","year":"2017","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"10.1016\/j.micpath.2023.106090_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175140","article-title":"Tigecycline resistance among carbapenem-resistant Klebsiella Pneumoniae: clinical characteristics and expression levels of efflux pump genes","volume":"12","author":"Chiu","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.micpath.2023.106090_bib53","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009961","article-title":"High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: a retrospective cohort study","volume":"97","author":"Geng","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.micpath.2023.106090_bib54","first-page":"118","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients","volume":"59","author":"Caston","year":"2017","journal-title":"Int. J. Infect. Dis. : IJID : official publication of the International Society for Infectious Diseases"},{"key":"10.1016\/j.micpath.2023.106090_bib55","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00698-21","article-title":"Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant enterobacterales","volume":"65","author":"Chen","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2023.106090_bib56","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bjid.2018.12.004","article-title":"Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection","volume":"23","author":"Liang","year":"2019","journal-title":"Braz. J. Infect. Dis. : an official publication of the Brazilian Society of Infectious Diseases"},{"key":"10.1016\/j.micpath.2023.106090_bib57","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/23744235.2021.2001046","article-title":"Short- versus prolonged-course antibiotic therapy for sepsis or infectious diseases in critically ill adults: a systematic review and meta-analysis","volume":"54","author":"Kubo","year":"2022","journal-title":"Infectious diseases"},{"key":"10.1016\/j.micpath.2023.106090_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002742","article-title":"COSMOS-E: guidance on conducting systematic reviews and meta-analyses of observational studies of etiology","volume":"16","author":"Dekkers","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.micpath.2023.106090_bib59","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1017\/ice.2017.197","article-title":"Carbapenem resistance, initial antibiotic therapy, and mortality in Klebsiella pneumoniae bacteremia: a systematic review and meta-analysis","volume":"38","author":"Kohler","year":"2017","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"10.1016\/j.micpath.2023.106090_bib60","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3201\/eid2007.121004","article-title":"Deaths attributable to carbapenem-resistant Enterobacteriaceae infections","volume":"20","author":"Falagas","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.micpath.2023.106090_bib61","doi-asserted-by":"crossref","first-page":"ofab026","DOI":"10.1093\/ofid\/ofab026","article-title":"Colistin nephrotoxicity: meta-analysis of randomized controlled trials","volume":"8","author":"Eljaaly","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.micpath.2023.106090_bib62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13756-021-00977-w","article-title":"Comparison of colistin-induced nephrotoxicity between two different formulations of colistin in critically ill patients: a retrospective cohort study","volume":"10","author":"Feng","year":"2021","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"10.1016\/j.micpath.2023.106090_bib63","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1371\/journal.pmed.0040079","article-title":"Selection in reported epidemiological risks: an empirical assessment","volume":"4","author":"Kavvoura","year":"2007","journal-title":"PLoS Med."},{"key":"10.1016\/j.micpath.2023.106090_bib64","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1136\/bmj.a117","article-title":"Reasons or excuses for avoiding meta-analysis in forest plots","volume":"336","author":"Ioannidis","year":"2008","journal-title":"BMJ"}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401023001237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401023001237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T06:31:25Z","timestamp":1736404285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401023001237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":61,"alternative-id":["S0882401023001237"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2023.106090","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2023.106090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106090"}}